keyword
MENU ▼
Read by QxMD icon Read
search

Pazopanib renal

keyword
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#1
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27842541/heterogeneous-response-and-progression-patterns-reveal-phenotypic-heterogeneity-of-tyrosine-kinase-inhibitor-response-in-metastatic-renal-cell-carcinoma
#2
Shanthini M Crusz, Yen Zhi Tang, Shah-Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltran, John Peters, Anju Sahdev, Axel Bex, Thomas Powles, Marco Gerlinger
BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the same patient. METHODS: We performed a retrospective central radiological analysis of patients with treatment-naïve metastatic ccRCC receiving anti-angiogenic tyrosine kinase inhibitors (TKIs) (sunitinib or pazopanib) within three similar phase II trials...
November 14, 2016: BMC Medicine
https://www.readbyqxmd.com/read/27823651/first-line-antiangiogenics-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#3
REVIEW
Benoît Rousseau, Emmanuelle Kempf, Gaelle Desamericq, Emilie Boissier, Marie Chaubet-Houdu, Charlotte Joly, Carolina Saldana, Helene Boussion, Cindy Neuzillet, Isabelle Macquin-Mavier, Stéphane Oudard, Laurent Salomon, Alexandre de la Taille, Christophe Tournigand
BACKGROUND: Sunitinib, pazopanib, sorafenib, axitinib and bevacizumab are the five recommended antiangiogenic agents in first-line therapy for metastatic renal cell carcinoma (mRCC). Because these drugs underwent simultaneous clinical development, no direct efficacy and safety comparison was ever conducted, thus preventing optimal therapy choices. METHODS: We performed a traditional and network meta-analysis to evaluate the efficacy and safety of mRCC-recommended first-line antiangiogenic agents...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27754995/prognostic-role-of-the-cumulative-toxicity-in-patients-affected-by-metastatic-renal-cells-carcinoma-and-treated-with-first-line-tyrosine-kinase-inhibitors
#4
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Ottavio de Cobelli, Franco Nolè
Tyrosine kinase inhibitor-related toxicities have been reported to be predictive and/or prognostic factors in patients affected by metastatic renal cell carcinoma (mRCC). We aim to investigate the incidence of cumulative toxicity and its prognostic role in mRCC patients treated with sunitinib or pazopanib. mRCC patients treated with sunitinib or pazopanib at the European Institute of Oncology in Milan were reviewed for the incidence of adverse events. Cumulative toxicity was defined as the presence of more than one selected adverse event of any grade...
October 14, 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27721266/a-comparison-of-drug-resistances-of-targeted-drugs-for-advanced-renal-cell-cancer-approved-by-the-food-and-drug-administration-a-meta-analysis-of-randomized-clinical-trials
#5
Ming Guo, Yunsong Cao, Jingzhe Yang, Jingfeng Zhang
PURPOSE: The purpose of this study was to conduct network meta-analysis to assess drug resistances of the Food and Drug Administration-approved drugs for advanced renal cell carcinoma. MATERIALS AND METHODS: Database searches were conducted to identify randomized controlled trials reporting results for eligible treatments. After searching for PubMed, MEDLINE, EMBASE, and ISI Web of Science, 22 studies (n = 7854 patients) were included for the comparison of drug resistance in the present meta-analysis...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27721264/meta-analysis-of-therapeutic-effects-and-the-risks-of-hypertension-and-hyperglycemia-in-patients-with-renal-cell-carcinoma-who-were-receiving-antiangiogenic-drugs
#6
Lingling Chang, Ying An, Shuling Yang, Xiaosu Zhang
PURPOSE: A meta-analysis of published data was conducted to investigate the therapeutic effects in patients with renal cell carcinoma (RCC) who were receiving antiangiogenic drugs. METHODS: A computerized search through electronic databases, including PubMed (until February 2016), was performed to obtain eligible randomized controlled trials that compared the effectiveness of antiangiogenic with control groups (everolimus, placebo, and interferon [IFN] alfa) in patients with RCC...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27699042/simultaneous-occurrence-of-non-hodgkin-lymphoma-renal-cell-carcinoma-and-oncocytoma-a-case-report
#7
Ewa Zabrocka, Ewa Sierko, Stefan Jelski, Marek Z Wojtukiewicz
We herein report the case of a 74 year-old woman with a diffuse large B-cell lymphoma and bilateral renal masses identified on computed tomography scans during the initial staging process. Following partial bilateral nephrectomy, histopathological examination revealed renal cell carcinoma (RCC) and oncocytoma in the left and the right kidneys, respectively. Shortly afterwards, lymphoma of the left palatine tonsil was diagnosed and the patient received chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP regimen), followed by radiotherapy...
October 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27664394/improvement-in-survival-end-points-of-patients-with-metastatic-renal-cell-carcinoma-through-sequential-targeted-therapy
#8
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, Viktor Grünwald, Bernard Escudier
Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus, and the programmed death-1 (PD-1) targeted immune checkpoint inhibitor nivolumab...
September 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27647404/-relationship-between-treatment-related-hypertension-and-therapeutic-efficacy-of-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-metastatic-renal-cell-carcinoma
#9
Y Song, C X Du, W Zhang, Y K Sun, L Yang, C X Cui, Yihebali Chi, A P Zhou, J W Wang, Y Sun
OBJECTIVE: Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) are widely used for the treatment of metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the association between treatment-related hypertension and the therapeutic efficacy of VEGFR-TKIs. METHODS: Clinical data of 155 mRCC patients treated with VEGFR-TKIs at the Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2014 were retrospectively analyzed...
September 23, 2016: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/27634566/dynamic-contrast-enhanced-magnetic-resonance-imaging-as-a-pharmacodynamic-biomarker-for-pazopanib-in-metastatic-renal-carcinoma
#10
Randy F Sweis, Milica Medved, Shannon Towey, Gregory S Karczmar, Aytekin Oto, Russell Z Szmulewitz, Peter H O'Donnell, Paul Fishkin, Theodore Karrison, Walter M Stadler
INTRODUCTION/BACKGROUND: Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is preceded by a rise in K(trans) level, a parameter derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) that reflects vascular permeability. We thus hypothesized that K(trans) might be a predictive biomarker for pazopanib...
August 17, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27630568/pazopanib-in-metastatic-renal-cancer-a-real-world-experience-at-national-cancer-institute-fondazione-g-pascale
#11
Sabrina C Cecere, Sabrina Rossetti, Carla Cavaliere, Chiara Della Pepa, Marilena Di Napoli, Anna Crispo, Gelsomina Iovane, Raffaele Piscitelli, Domenico Sorrentino, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdonà, Massimiliano Berretta, Sandro Pignata, Gaetano Facchini, Carmine D'Aniello
Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective, observational nature and the unselected population, our experience can be defined a "real-world" study. The medical records of 38 mRCC patients treated with front-line pazopanib were retrospectively reviewed and analyzed...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27625016/clinical-effect-of-dose-escalation-after-disease-progression-in-patients-with-metastatic-renal-cell-carcinoma
#12
Moshe C Ornstein, Laura Wood, Paul Elson, Kimberly Allman, Jennifer Beach, Allison Martin, Timothy Gilligan, Jorge A Garcia, Brian I Rini
BACKGROUND: Given the variability in drug levels with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC), dose escalation at the occurrence of progressive disease (PD) might have antitumor effects. PATIENTS AND METHODS: The data from patients with mRCC who were treated at the Cleveland Clinic with TKIs and received a dose escalation after PD in accordance with Response Evaluation Criteria In Solid Tumors (RECIST), version 1...
August 18, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27601362/posterior-reversible-encephalopathy-syndrome-with-concurrent-nephrotic-syndrome-in-a-patient-treated-with-pazopanib-for-metastatic-renal-cell-carcinoma-case-report-and-review-of-the-literature
#13
Nikolaos Miaris, Maria Maltezou, George Papaxoinis, Anastasios Visvikis, Epaminontas Samantas
No abstract text is available yet for this article.
August 10, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27592258/myopodin-methylation-is-a-prognostic-biomarker-and-predicts-antiangiogenic-response-in-advanced-kidney-cancer
#14
N Pompas-Veganzones, V Sandonis, Alberto Perez-Lanzac, M Beltran, P Beardo, A Juárez, F Vazquez, J M Cozar, J L Alvarez-Ossorio, Marta Sanchez-Carbayo
Myopodin is a cytoskeleton protein that shuttles to the nucleus depending on the cellular differentiation and stress. It has shown tumor suppressor functions. Myopodin methylation status was useful for staging bladder and colon tumors and predicting clinical outcome. To our knowledge, myopodin has not been tested in kidney cancer to date. The purpose of this study was to evaluate whether myopodin methylation status could be clinically useful in renal cancer (1) as a prognostic biomarker and 2) as a predictive factor of response to antiangiogenic therapy in patients with metastatic disease...
September 3, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/27568124/outcomes-of-patients-with-metastatic-non-clear-cell-renal-cell-carcinoma-treated-with-pazopanib
#15
Marc R Matrana, Ali Baiomy, Matthew Campbell, Suhail Alamri, Aditya Shetty, Purnima Teegavarapu, Sarathi Kalra, Lianchun Xiao, Bradley Atkinson, Paul Corn, Eric Jonasch, Khaled M Elsayes, Nizar M Tannir
BACKGROUND: Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited. PATIENTS AND METHODS: We conducted a retrospective data analysis of records of consecutive metastatic non-clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012...
July 22, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27556889/clinical-pharmacology-drug-drug-interactions-and-safety-of-pazopanib-a-review
#16
Pascaline Boudou-Rouquette, Camille Tlemsani, Benoit Blanchet, Olivier Huillard, Anne Jouinot, Jennifer Arrondeau, Audrey Thomas-Schoemann, Michel Vidal, Jérôme Alexandre, François Goldwasser
In the past decade, treatment options for metastatic renal cell carcinoma and soft-tissue sarcoma have expanded. Pazopanib was discovered during the screening of compounds that suppressed vascular endothelial growth factor receptor-2 (VEGFR-2). As other tyrosine kinase inhibitors (TKI), pazopanib is not totally specific for one target since it also inhibits stem-cell factor receptor (cKIT), platelet-derived growth factor receptors (PDGFRα, β), VEGFR-1 and -3. Areas covered: Clinical pharmacology, drug-drug interactions and safety data published on pazopanib, between January 2006 and April 2016, are reviewed...
December 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27549785/effect-of-the-timing-of-best-tumor-shrinkage-on-survival-of-patients-with-metastatic-renal-cell-carcinoma-who-received-first-line-tyrosine-kinase-inhibitor-therapy
#17
Hiroki Ishihara, Takafumi Yagisawa, Tsunenori Kondo, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Kazunari Tanabe
BACKGROUND: To evaluate the association between the timing of best tumor shrinkage (bTS) and metastatic renal cell carcinoma (mRCC) patient survival after first-line tyrosine kinase inhibitor (TKI) therapy. METHODS: The tumors of 91 patients with mRCC showed a response to TKIs. None of the patients had received prior cytokine therapy. The magnitude of bTS was categorized according to the Response Evaluation Criteria in Solid Tumors v. 1.1. The patients were divided into two subgroups according to the timing of bTS: early responders (≤3 months) and late responders (>3 months)...
August 22, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27536183/cost-effectiveness-of-pazopanib-compared-with-sunitinib-in-metastatic-renal-cell-carcinoma-in-canada
#18
J Amdahl, J Diaz, J Park, H R Nakhaipour, T E Delea
BACKGROUND: In Canada and elsewhere, pazopanib and sunitinib-tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors-are recommended as first-line treatment for patients with metastatic renal cell carcinoma (mrcc). A large randomized noninferiority trial of pazopanib versus sunitinib (comparz) demonstrated that the two drugs have similar efficacy; however, patients randomized to pazopanib experienced better health-related quality of life (hrqol) and nominally lower rates of non-study medical resource utilization...
August 2016: Current Oncology
https://www.readbyqxmd.com/read/27515221/changes-in-metabolic-profile-iron-and-ferritin-levels-during-the-treatment-of-metastatic-renal-cancer-a-new-potential-biomarker
#19
Marin Golčić, Marija Petković
Metastatic renal cell carcinoma (mRCC) develops in approximately 33% of all renal cancer patients. First line treatment of mRCC includes drugs such as sunitinib, temsirolimus and pazopanib, with overall survival now reaching up to 43,6months in patients with favorable-risk metastatic disease. Several side-effects in mRCC treatment, such as hypothyroidism, can be used as positive prognostic factors and indicate good response to therapy. Hypercholesterolemia and hypertriglyceridemia independent of hypothyroidism are reported as side-effects in temsirolimus treatment and recently in sunitinib treatment, but the exact mechanism and significance of the changes remains elusive...
September 2016: Medical Hypotheses
https://www.readbyqxmd.com/read/27513367/dynamic-contrast-enhanced-computed-tomography-derived-blood-volume-and-blood-flow-correlate-with-patient-outcome-in-metastatic-renal-cell-carcinoma
#20
Jill Rachel Mains, Frede Donskov, Erik Morre Pedersen, Hans Henrik Torp Madsen, Finn Rasmussen
OBJECTIVES: The aim was to explore the potential for using dynamic contrast-enhanced computed tomography as a noninvasive functional imaging biomarker before and during the early treatment of metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Dynamic contrast-enhanced computed tomography scans were performed at baseline and after 5 and 10 weeks' treatment in 69 prospectively included mRCC patients receiving treatment with interferon alpha and interleukin 2 (n = 26); interferon alpha, interleukin 2, and bevacizumab (n = 24); sunitinib (n = 7); pazopanib (n = 5); or temsirolimus (n = 7)...
August 10, 2016: Investigative Radiology
keyword
keyword
113200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"